EUCTR2007-003638-40-DE进行中（未招募）不适用
A Double-blind, Randomized, Placebo-controlled, Parallel, Multicenter Study of the Safety and Efficacy of Two Dosages of Bicifadine SR in Adult Outpatients with Chronic Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 336
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female, of any race, age 18 years or older
- •2.Diagnosis of type-I (insulin dependent) or type-II (non-insulin dependent) diabetes mellitus
- •3.Hemoglobin A1C of =11%
- •4.Evidence of chronic bilateral pain due to diabetic neuropathy, which is defined as pain in the legs or feet with decreased sensation in the feet or decreased/absent ankle jerk deep tendon reflexes
- •5.Neuropathy diagnosis confirmed by a score of =3 on the Michigan Neuropathy Screening Instrument (MNSI) Part B only.
- •6.Presence of pain due to chronic diabetic neuropathy for at least 6 months prior to the initial screening visit
- •7.The primary pain location must be in the feet
- •8.For females, subjects of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year) must be using appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectable, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner). Oral contraceptive medications are allowed in this study
- •9.Subject must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
- •10.Subject must give written informed consent to participate. There must be evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent procedures of the study prior to performing any study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Presence of other pain that could confound assessment or self-evaluation of the pain due to chronic diabetic neuropathy such as peripheral vascular disease (ischemic pain), neurological disorders unrelated to diabetic neuropathy (e.g., phantom limb pain from amputation), skin condition in the area of the neuropathy that could alter sensation (e.g., plantar ulcer), or other painful conditions (e.g., arthritis, fibromyalgia)
- •2.Symptoms of other painful conditions such as thoracic radiculopathy or lumbar radiculopathy that could confound assessment or self-evaluation of the pain due to chronic diabetic neuropathy
- •3.Presence of amputations other than toe amputations
- •4.History of lack of analgesic response to an adequate trial of duloxetine, venlafaxine, or tricyclic antidepressants (TCAs)
- •5.Score of >20 on the BDI
- •6.History of any clinically significant psychiatric or other neurological disorder other than diabetic neuropathy, headache, or migraine headache
- •7.Significant neurological or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately (e.g., Alzheimer’s disease or schizophrenia or other psychosis), that in the investigator’s opinion may affect efficacy or safety assessments or may compromise subject safety during the trial
- •8.History (within the last 10 years) of any seizure disorder or epilepsy
- •9.Any of the following within 1 year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm. Severe traumatic brain injury within the last 10 years
- •10.Use of the following medications (which could affect symptoms of pain due to chronic diabetic neuropathy) during the study: TCAs, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin, other AEDs (such as carbamazepine), baclofen, mexiletine, capsaicin, tramadol, opioids, or other analgesics (except for acetaminophen up to 3 g/day and prophylactic aspirin up to 325 mg/day). All of these excluded medications require a washout period of appropriate length (according to the investigator) before the Screening II Visit.
- •11.Current evidence of clinically important diseases of gastrointestinal, hematopoietic, renal, respiratory, or cardiovascular systems; urinary retention; or glaucoma
- •12.Female subjects who are pregnant and/or breastfeeding or have a positive serum pregnancy test at the Screening or Baseline Visits
- •13.Positive urine drug screen for amphetamines, barbiturates, marijuana metabolites, cocaine metabolites, methadone, methaqualone, opiates, phencyclidine (PCP), or propoxyphene. However, a positive urine drug screen for benzodiazepines will not necessarily exclude the subject.
- •14.History of known alcohol or narcotic substance abuse within 2 years prior to the initial screening visit
- •15.History of any chronic illness other than diabetes that may interfere with or contraindicate participation in the study, as determined by the investigator
- •16.A body mass index (BMI) of greater than 40
- •17.Clinically-relevant illness within the 30 days prior to the initial screening visit that may interfere with the subject’s ability to complete the study
- •18.Participated in a previous clinical study of bicifadine
- •19.Any subject considering or scheduled to undergo any major surgical procedure during the study period
- •20.Any subject who has taken any other investigational drug during the 30 days prior to the initial screening v
研究者
相似试验
进行中（未招募）
1 期
Evaluation of Dupilumab in Children with Uncontrolled Asthma (Liberty Asthma Voyage)MedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2016-001607-23-HUSanofi-Aventis Recherche & Développement785
进行中（未招募）
1 期
Effect of Efpeglenatide on Cardiovascular OutcomesType 2 diabetes mellitusMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-002954-35-FIsanofi-aventis recherche & développement5,000
进行中（未招募）
1 期
A Clinical Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s DiseaseEarly Alzheimer’s DiseaseMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2020-000116-30-SEJanssen-Cilag International NV420
进行中（未招募）
1 期
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskType 2 diabetes mellitusChronic kidney diseaseMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2017-002644-32-NOSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT16,154
进行中（未招募）
1 期
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-006165-11-PLJanssen-Cilag International NV350